Skip to main content
  • IMPORTANT SAFETY INFORMATION
  • PRESCRIBING INFORMATION
    • Prescribing Information — English PDF
    • Prescribing Information — Spanish PDF
  • MEDICATION GUIDE
  • REMS PROGRAM
  • SIGN UP FOR UPDATES
  • FOR US PATIENTS & CAREGIVERS
  • VISIT US HEALTHCARE PROFESSIONAL SITE
  • SIGN UP FOR UPDATES
  • US Healthcare Professionals

Carvykti Logo

SIGN UP FOR UPDATES
  • HOME
  • ABOUT CARVYKTI™
    • How CARVYKTI™ works
    • Clinical efficacy
    • Safety profile
  • RECEIVING CARVYKTI™
    • The CARVYKTI™ treatment process
    • Planning for treatment with CARVYKTI™
  • RESOURCES AND SUPPORT
    • Patient resources
    • Caregiver support
  • PATIENT STORIES
  • FIND A CERTIFIED TREATMENT CENTER

SIGN UP FOR UPDATES

  • IMPORTANT SAFETY INFORMATION
  • PRESCRIBING INFORMATION
    • Prescribing Information — English PDF
    • Prescribing Information — Spanish PDF
  • MEDICATION GUIDE
  • REMS PROGRAM
  • SIGN UP FOR UPDATES
  • FOR US PATIENTS & CAREGIVERS
  • VISIT US HEALTHCARE PROFESSIONAL SITE

Sign Up For Updates

STAY INFORMED THROUGHOUT YOUR TREATMENT JOURNEY

Tell us a little bit about yourself to get tailored communications and support materials designed for your needs

The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers to provide you information and updates about CARVYKTI™ and communications to support you at certain points throughout your treatment experience. Due to the personalized nature of the therapy, there may be circumstances where we may need to discontinue these communications. If that is the case, you may no longer receive these communications or the communications may differ slightly. Our Privacy Policy further governs the use of information you provide. By providing the information and selecting the SUBMIT button, you indicate that you have read, understand, and agree with these terms.

*Required fields

What is CARVYKTI™ (ciltacabtagene autoleucel)?
  • CARVYKTI™ is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least four other kinds of treatment have not worked or have stopped working
  • CARVYKTI™ is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells
IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CARVYKTI™?

CARVYKTI™ may cause side effects that are severe or life-threatening and can lead to death. Call your healthcare provider or get emergency help right away if you get any of the following:

  • fever (100.4°F/38°C or higher)
  • chills or shaking chills
  • fast or irregular heartbeat
  • difficulty breathing
  • very low blood pressure
  • dizziness/light headedness
  • effects on your nervous system, some of which can occur days or weeks after you receive the infusion, and may initially be subtle such as:
    • feeling confused, less alert or disoriented, having difficulty speaking or slurred speech, having difficulty reading, writing and understanding words, memory loss
    • loss of coordination affecting movement and balance, slower movements, changes in handwriting
    • personality changes including a reduced ability to express emotions, being less talkative, disinterest in activities, and reduced facial expression
    • tingling, numbness and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing
    • facial numbness, difficulty moving muscles of face and eyes

It is important that you tell your healthcare providers that you have received CARVYKTI™ and to show them your CARVYKTI™ Patient Wallet Card. Your healthcare providers may give you other medicines to treat your side effects.

How will I receive CARVYKTI™?

  • CARVYKTI™ is made from your own white blood cells, so your blood will be collected by a process called “leukapheresis.” The procedure can take 3 to 6 hours and may need to be repeated
  • Your white blood cells are sent to a manufacturing center to make CARVYKTI™. It takes about 4-5 weeks from the time your cells are received at the manufacturing site and are available to be shipped back to your healthcare provider, but the time may vary
  • While CARVYKTI™ is being made, you may get other medicines to treat the multiple myeloma. This is so that your multiple myeloma does not get worse

Before you get CARVYKTI™, your healthcare provider will give you chemotherapy for 3 days to prepare your body.

30 to 60 minutes before you are given CARVYKTI™, you may be given other medicines. These may include:

  • medicines for an allergic reaction (antihistamines)
  • medicines for fever (such as acetaminophen)

When your CARVYKTI™ is ready, your healthcare provider will give CARVYKTI™ to you through a catheter (tube) placed into your vein (intravenous infusion). Your dose of CARVYKTI™ will be given in one infusion bag. The infusion usually takes approximately 30-60 minutes.

After getting CARVYKTI™, you will be monitored at the certified healthcare facility where you received your treatment for at least 10 days after the infusion.

You should plan to stay close to the location where you received your treatment for at least 4 weeks. Your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur. You may be hospitalized if you develop serious side effects until your side effects are under control and it is safe for you to leave the hospital.

Your healthcare provider will want to do blood tests to follow your progress. It is important that you have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.

What should I avoid after receiving CARVYKTI™?

Do not drive, or operate heavy machinery, or do other activities that could be dangerous if you are not mentally alert, for at least 8 weeks after you receive CARVYKTI™. This is because the treatment can cause memory and coordination problems, sleepiness, confusion, dizziness, seizures, or other neurologic side effects as discussed by your healthcare provider.

  • You must not be given certain vaccines called live vaccines for some time before and after CARVYKTI™ treatment. Talk to your healthcare provider if you need to have any vaccinations
  • Do not donate blood, organs, tissues, or cells for transplantation

What are the possible or reasonably likely side effects of CARVYKTI™?

The most common side effects of CARVYKTI™ include:

  • fever (100.4°F/38°C or higher), chills
  • dizziness or light-headedness
  • headache, muscle or joint pain, feeling very tired
  • altered mental state, confusion
  • infections
  • low levels of antibodies (immunoglobulins) in the blood
  • cough, being short of breath
  • diarrhea, nausea, decreased appetite, constipation
  • fast or irregular heartbeat
  • problems with blood clotting

CARVYKTI™ can cause a very common side effect called cytokine release syndrome or CRS, which can be severe or fatal. Symptoms of CRS include fever, difficulty breathing, dizziness or lightheadedness, nausea, headache, fast heartbeat, low blood pressure, or fatigue. Tell your healthcare provider right away if you develop fever or any of these other symptoms after receiving CARVYKTI™.

CARVYKTI™ can increase the risk of life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

CARVYKTI™ can cause various neurologic side effects, some of which may be severe or fatal. Symptoms include but are not limited to confusion, disorientation, loss of consciousness, seizures, difficulty speaking, reading or writing, tremor, slower movements, changes in personality, depression, tingling and numbness of hands and feet, leg and arm weakness, and facial numbness.

CARVYKTI™ can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets [cells that help blood to clot]), which may make you feel weak or tired, or increase your risk of severe infection or bleeding. After treatment, your healthcare provider will test your blood to check for this. Tell your healthcare provider right away if you get a fever, chills, or any signs or symptoms of an infection, are feeling tired, or have bruising or bleeding.

Having CARVYKTI™ in your blood may cause some commercial Human immunodeficiency virus (HIV) tests to incorrectly give you an HIV-positive result even though you may be HIV-negative.

These are not all the possible side effects of CARVYKTI™. Call your healthcare provider if you have any side effect.

You may report side effects to FDA at 1-800-FDA-1088.

 

cp-258861v2

Share page with AddThis
  • Contact Us
  • Sitemap
Janssen Oncology Logo
Legend Biotech logo

© Janssen Biotech, Inc. , and Legend Biotech 2022 All rights reserved.

© Legend Biotech 2022 All rights reserved.

This site is published by Janssen Biotech, Inc., and Legend Biotech, which is solely responsible for its contents. The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.

This information is intended for the use of patients and caregivers in the United States and Puerto Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice |  | 

Do not sell my personal information

Last updated May 2022 | cp-218489v1cp-269685v1

You are leaving the CARVYKTI™ (ciltacabtagene autoleucel) website

You are being redirected to a third-party website:

[extlink:external-url]

This link is provided for your convenience. Please note that this third-party website is not controlled by CARVYKTI™ or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

Continue
Cancel
Loading Common Footer...